- Home
- YYAI vs LPTX Comparison
YYAI vs LPTX Comparison
Compare YYAI & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- LPTX
- Stock Information
- Founded
- YYAI 2015
- LPTX 2011
- Country
- YYAI Hong Kong
- LPTX United States
- Employees
- YYAI N/A
- LPTX N/A
- Industry
- YYAI
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YYAI
- LPTX Health Care
- Exchange
- YYAI NYSE
- LPTX Nasdaq
- Market Cap
- YYAI 13.7M
- LPTX 14.7M
- IPO Year
- YYAI N/A
- LPTX N/A
- Fundamental
- Price
- YYAI $3.15
- LPTX $0.36
- Analyst Decision
- YYAI
- LPTX Hold
- Analyst Count
- YYAI 0
- LPTX 1
- Target Price
- YYAI N/A
- LPTX N/A
- AVG Volume (30 Days)
- YYAI 2.3M
- LPTX 441.4K
- Earning Date
- YYAI 09-09-2025
- LPTX 08-11-2025
- Dividend Yield
- YYAI N/A
- LPTX N/A
- EPS Growth
- YYAI N/A
- LPTX N/A
- EPS
- YYAI N/A
- LPTX N/A
- Revenue
- YYAI N/A
- LPTX N/A
- Revenue This Year
- YYAI N/A
- LPTX N/A
- Revenue Next Year
- YYAI N/A
- LPTX N/A
- P/E Ratio
- YYAI N/A
- LPTX N/A
- Revenue Growth
- YYAI N/A
- LPTX N/A
- 52 Week Low
- YYAI $0.35
- LPTX $0.22
- 52 Week High
- YYAI $16.90
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- YYAI 92.47
- LPTX 55.27
- Support Level
- YYAI $0.84
- LPTX $0.33
- Resistance Level
- YYAI $1.48
- LPTX $0.38
- Average True Range (ATR)
- YYAI 0.36
- LPTX 0.03
- MACD
- YYAI 0.22
- LPTX 0.01
- Stochastic Oscillator
- YYAI 75.37
- LPTX 79.07
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.